Jessica P Rajan1, Nathan E Wineinger2, Donald D Stevenson3, Andrew A White3. 1. Department of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, Calif. Electronic address: jessicarajan@gmail.com. 2. Scripps Translational Science Institute, San Diego, Calif. 3. Department of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, Calif.
Abstract
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is manifested by adult-onset asthma, nasal polyposis, chronic rhinosinusitis, and aspirin sensitivity. Previously reported prevalence rates have been widely variable based on the population studied, method of diagnosis, and definition of aspirin sensitivity. OBJECTIVE: We sought to determine the prevalence of AERD among asthmatic adults. METHODS: A systematic review of databases was performed to identify all clinical trials published on or before June 16, 2013, that evaluated the prevalence of AERD. The studies were clustered into 7 different groups based on underlying disease (asthma, nasal polyps or chronic rhinosinusitis, or both), as well as on the methodology of prevalence determination. RESULTS: A total of 1770 articles were identified, with 27 considered appropriate for inclusion. Prevalence rates of AERD ranged from 5.5% to 12.4% based on study type. Among all studies in asthmatic patients, regardless of method, the prevalence of AERD was 7.15% (95% CI, 5.26% to 9.03%). The prevalence of AERD was highest among patients with severe asthma (14.89% [95% CI, 6.48% to 23.29%]). Among patients with nasal polyps and chronic rhinosinusitis, the prevalence was 9.69% (95% CI, 2.16% to 17.22%) and 8.7% (95% CI, -1.02% to 18.34%), respectively. CONCLUSION: AERD is a distinct and important subtype of asthma and polypoid sinus disease. The prevalence of AERD is 7% in typical adult asthmatic patients and twice that number in patients with severe asthma, which underscores the importance of recognizing this disorder. Early identification of this syndrome is critical in view of the increased morbidity and costs associated with asthma exacerbations and the option to treat patients with AERD with long-term aspirin treatment after desensitization.
BACKGROUND:Aspirin-exacerbated respiratory disease (AERD) is manifested by adult-onset asthma, nasal polyposis, chronic rhinosinusitis, and aspirin sensitivity. Previously reported prevalence rates have been widely variable based on the population studied, method of diagnosis, and definition of aspirin sensitivity. OBJECTIVE: We sought to determine the prevalence of AERD among asthmatic adults. METHODS: A systematic review of databases was performed to identify all clinical trials published on or before June 16, 2013, that evaluated the prevalence of AERD. The studies were clustered into 7 different groups based on underlying disease (asthma, nasal polyps or chronic rhinosinusitis, or both), as well as on the methodology of prevalence determination. RESULTS: A total of 1770 articles were identified, with 27 considered appropriate for inclusion. Prevalence rates of AERD ranged from 5.5% to 12.4% based on study type. Among all studies in asthmatic patients, regardless of method, the prevalence of AERD was 7.15% (95% CI, 5.26% to 9.03%). The prevalence of AERD was highest among patients with severe asthma (14.89% [95% CI, 6.48% to 23.29%]). Among patients with nasal polyps and chronic rhinosinusitis, the prevalence was 9.69% (95% CI, 2.16% to 17.22%) and 8.7% (95% CI, -1.02% to 18.34%), respectively. CONCLUSION: AERD is a distinct and important subtype of asthma and polypoid sinus disease. The prevalence of AERD is 7% in typical adult asthmatic patients and twice that number in patients with severe asthma, which underscores the importance of recognizing this disorder. Early identification of this syndrome is critical in view of the increased morbidity and costs associated with asthma exacerbations and the option to treat patients with AERD with long-term aspirin treatment after desensitization.
Authors: Katherine L Tuttle; Thomas R Schneider; Sarah E Henrickson; David Morris; Juan Pablo Abonia; Jonathan M Spergel; Tanya M Laidlaw Journal: J Allergy Clin Immunol Pract Date: 2016 Jul-Aug
Authors: Elina Jerschow; Matthew L Edin; Teresa Pelletier; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin Fried; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Weiguo Han; Golda Hudes; Taha Keskin; Victor L Schuster; Simon Spivack; Darryl C Zeldin; David Rosenstreich Journal: J Allergy Clin Immunol Pract Date: 2017-01-31
Authors: Whitney W Stevens; Christopher J Ocampo; Sergejs Berdnikovs; Masafumi Sakashita; Mahboobeh Mahdavinia; Lydia Suh; Tetsuji Takabayashi; James E Norton; Kathryn E Hulse; David B Conley; Rakesh K Chandra; Bruce K Tan; Anju T Peters; Leslie C Grammer; Atsushi Kato; Kathleen E Harris; Roderick G Carter; Shigeharu Fujieda; Robert C Kern; Robert P Schleimer Journal: Am J Respir Crit Care Med Date: 2015-09-15 Impact factor: 21.405
Authors: Katherine N Cahill; Christina B Johns; Jing Cui; Paige Wickner; David W Bates; Tanya M Laidlaw; Patrick E Beeler Journal: J Allergy Clin Immunol Date: 2016-07-25 Impact factor: 10.793